Angiogenesis Inhibitors in Small Cell Lung Cancer

Frontiers in Oncology

Guido Carillio¹  Priscilla Cascetta²  Nicola Normanno³  Maria C. Piccirillo³  Gerardo Botti⁴  Giacomo Pascarella⁴  Agnese Montanino⁵  Raffaele Costanzo⁵  Vincenzo Sforza⁵  Alessandro Morabito⁵  Giovanna Esposito⁵  Giuliano Palumbo⁵  Claudia Sandomenico⁵  Carmine La Manna⁵  Anna Manzo⁵ 

[1] Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;Oncology Department, University Federico II, Naples, Italy;Scientific Department, Istituto Nazionale Tumori, “Fondazione G.Pascale” – IRCCS, Naples, Italy;Scientific Directorate, Istituto Nazionale Tumori, “Fondazione G. Pascale” - IRCCS, Naples, Italy;Thoracic Department, Istituto Nazionale Tumori, IRCCS “Fondazione G.Pascale”, Naples, Italy;

关键词: small cell lung cancer;    angiogenesis;    vascular endothelial growth factor;    bevacizumab;    anlotinib;   

DOI  :  10.3389/fonc.2021.655316

来源: DOAJ

【 摘 要 】

Inhibition of angiogenesis has been demonstrated to be an efficacious strategy in treating several tumors. Vascular endothelial growth factor (VEGF) is the most important protein with proangiogenic functions and it is overexpressed in small cell lung cancer (SCLC). Bevacizumab, a monoclonal antibody directed against VEGF, showed a promising activity in combination with etoposide and cisplatin as first-line treatment of patients with extended stage (ES)-SCLC and two randomized studies confirmed that bevacizumab improved PFS, but failed to prolong OS. Instead, disappointing results have been observed with endostar, sunitinib, sorafenib, vandetanib, and thalidomide in combination with chemotherapy in the first-line setting, with sunitinib in the maintenance setting, with sunitinib, cediranib and nintedanib as single agents or ziv-aflibercept in combination with topotecan in second-line setting. Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.

【 授权许可】

Unknown